RXRA and Hyperglycemia: We then evaluated the binding abilities by ChIP analysis on the CYP19A1 promoter using antibodies for the following transcription factors: Sp1, RXRα, RORA, PU.1, and SRF and found that the binding ability of RORA on the CYP19A1 promoter decreased to 49% as a result of hyperglycemia treatment (HG(4d)+LG(4d)/CTL) compared to control (LG(4d)+LG(4d)/CTL) treatment.